LetterTo The EditorProbing the Future Use of Half-Dose DOAC Monotherapy After Left Atrial Appendage Closure
To The Editor
Under an Elsevier user license
open archive
Cited by (0)
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation